Diamyd Medical provides update on clinical studies with Diamyd®
Diamyd Medical (Nasdaq First North, Stockholm, DMYD B) participates in six clinical studies with the diabetes vaccine Diamyd® for the treatment and prevention of type 1 diabetes. The Company announced today that yet another of these, the phase II study EDCR IIa now is fully enrolled and that results from a first evaluation after 6 months are estimated to be presented during the second quarter of 2017. The Company also announced that results from the placebo-controlled prevention study DiAPREV-IT 1 are expected to be presented during the first quarter of 2017.All 20 patients are now included